Adamis Pharmaceuticals said federal regulators have given it a green light to produce Symjepi, an emergency injection treatment for allergic reactions, providing a potential competitor to Mylan NV’s EpiPen.
from WSJ.com: US Business http://ift.tt/2suuXlP
via IFTTT
No comments:
Post a Comment